Compare Neurocrine Biosciences Inc (NBIX) vs USA Rare Earth Inc. Class A Common Stock (USAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs USA Rare Earth Inc. Class A Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $135.83 (market cap $14.37B), while USA Rare Earth Inc. Class A Common Stock trades at $10.22 (market cap $4.23B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.4× USA Rare Earth Inc. Class A Common Stock's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, USA Rare Earth Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 24 Days and USA Rare Earth Inc. Class A Common Stock for 0 Days on average.
| NBIX | USAR | |
|---|---|---|
Market Cap | $14.37B | $4.23B |
Volume | 1,081,559 | 13,677,660 |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $33.68 |
52-Week Low | $123.10 | $10.32 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $14.38B | $2.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $135.13, down 4.41% over 24 hours amid a broader bearish technical signal, though key moving averages and oscillators show mixed signals. Fundamentally, the company demonstrates robust health with a 97.91% gross profit margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 against a $1.85 expectation. Recent news highlights pipeline advancements, including presentations on Prader-Willi syndrome research and executive appointments, supporting long-term growth narratives beyond its flagship product INGREZZA.
The investment outlook for NBIX is positive, driven by strong analyst consensus with a $204.18 price target and 86.49% buy ratings, reflecting confidence in revenue growth and pipeline diversification. Key risks include execution challenges in commercializing new products and potential pricing pressures on INGREZZA post-2029. Investors should weigh the company's high profitability and cash flow generation against these sector-specific headwinds.
USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.
The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About USA Rare Earth Inc. Class A Common Stock
USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.
Read more on USAR →
